Gene therapy injection aims to treat dry AMD

NCT ID NCT07024732

Completed Disease control Sponsor: Eyevensys Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests the safety of a single injection of PST-611, a DNA-based therapy, in people aged 50 and older with dry age-related macular degeneration (AMD). The therapy is designed to make the eye produce a protein that may protect against vision loss. Participants receive one dose and are monitored for 16 weeks to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PST-611 (a DNA-based therapy injected into the eye muscle)
What this could lead to: If safe and effective, this approach could offer a new way to treat dry age-related macular degeneration by helping the eye produce a protective protein.
What could go wrong: This is a very early, small trial (8 people) focused only on safety, not on whether the treatment works. Side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY AGE RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY AGE RELATED MACULAR DEGENERATION

Contacts and locations

Show contact details

Locations

CHU de Grenoble-Hôpital Michallon

Grenoble, France, 38043, France
Hôpital Cochin

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.